If combining FasL and P-gp according to rank by the immunohistochemistry, patients with higher expression (++/+++) of both molecules showed worse prognosis than patients with lower expression (−/+) in CRC (Figure 3E) and GC (Figure 3F). This evidence concerns the gene PGP and colorectal carcinoma.